Search research articles
Contact Us
Filters
Showing results (31-40 of 164) with videos related to
Page
of 17
Sort By:
Investigational New Drugs
|
July 8, 2010
Cediranib in combination with various anticancer regimens: results of a phase I multi-cohort study
Patricia Lorusso, Anthony F Shields, Shirish Gadgeel, et al.
Investigational New Drugs
|
August 4, 2011
A phase I pharmacokinetic and safety evaluation of oral pazopanib dosing administered as crushed tablet or oral suspension in patients with advanced solid tumors
Elisabeth I Heath, Karen Forman, Lisa Malburg, et al.
Journal of Clinical Pharmacology
|
October 20, 2009
Clinical pharmacokinetics and exposure-toxicity relationship of a folate-Vinca alkaloid conjugate EC145 in cancer patients
Jing Li, Edward A Sausville, Patrick J Klein, et al.
Investigational New Drugs
|
March 4, 2005
Phase II trial of fenretinide in advanced renal carcinoma
Ulka Vaishampayan, Lance K Heilbrun, Ralph E Parchment, et al.
Plos One
|
April 16, 2011
Targeted morphoproteomic profiling of Ewing's sarcoma treated with insulin-like growth factor 1 receptor (IGF1R) inhibitors: response/resistance signatures
Vivek Subbiah, Aung Naing, Robert E Brown, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 15, 2004
Factors associated with breast cancer clinical trials participation and enrollment at a large academic medical center
Michael S Simon, Wei Du, Lawrence Flaherty, et al.
Investigational New Drugs
|
July 3, 2013
Phase 1 dose-escalation, pharmacokinetic, and cerebrospinal fluid distribution study of TAK-285, an investigational inhibitor of EGFR and HER2
Patricia LoRusso, Karthik Venkatakrishnan, E Gabriela Chiorean, et al.
The Oncologist
|
February 12, 2015
Phase I dose-escalation study of pilaralisib (SAR245408, XL147), a pan-class I PI3K inhibitor, in combination with erlotinib in patients with solid tumors
Jean-Charles Soria, Patricia LoRusso, Ratislav Bahleda, et al.
Cancer Investigation
|
July 28, 2023
Platinum Sensitivity in <i>IDH1/2</i> Mutated Intrahepatic Cholangiocarcinoma: Not All "BRCAness" Is Created Equal
Deborah Blythe Doroshow, Wei Wei, Meenakshi Mehrotra, et al.
Journal of Cancer Therapy
|
September 24, 2013
Physicians' Use of Patients' Daily Reports of Quality of Life to Evaluate Treatment Response in Phase I Cancer Trials
Felicity W K Harper, Elisabeth I Heath, Marci E J Gleason, et al.
Page
of 17
Search research articles
Search
Showing results (31-40 of 164) with videos related to
Sort By:
Page
of 17
Investigational New Drugs
|
July 8, 2010
Cediranib in combination with various anticancer regimens: results of a phase I multi-cohort study
Patricia Lorusso, Anthony F Shields, Shirish Gadgeel, et al.
Investigational New Drugs
|
August 4, 2011
A phase I pharmacokinetic and safety evaluation of oral pazopanib dosing administered as crushed tablet or oral suspension in patients with advanced solid tumors
Elisabeth I Heath, Karen Forman, Lisa Malburg, et al.
Journal of Clinical Pharmacology
|
October 20, 2009
Clinical pharmacokinetics and exposure-toxicity relationship of a folate-Vinca alkaloid conjugate EC145 in cancer patients
Jing Li, Edward A Sausville, Patrick J Klein, et al.
Investigational New Drugs
|
March 4, 2005
Phase II trial of fenretinide in advanced renal carcinoma
Ulka Vaishampayan, Lance K Heilbrun, Ralph E Parchment, et al.
Plos One
|
April 16, 2011
Targeted morphoproteomic profiling of Ewing's sarcoma treated with insulin-like growth factor 1 receptor (IGF1R) inhibitors: response/resistance signatures
Vivek Subbiah, Aung Naing, Robert E Brown, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 15, 2004
Factors associated with breast cancer clinical trials participation and enrollment at a large academic medical center
Michael S Simon, Wei Du, Lawrence Flaherty, et al.
Investigational New Drugs
|
July 3, 2013
Phase 1 dose-escalation, pharmacokinetic, and cerebrospinal fluid distribution study of TAK-285, an investigational inhibitor of EGFR and HER2
Patricia LoRusso, Karthik Venkatakrishnan, E Gabriela Chiorean, et al.
The Oncologist
|
February 12, 2015
Phase I dose-escalation study of pilaralisib (SAR245408, XL147), a pan-class I PI3K inhibitor, in combination with erlotinib in patients with solid tumors
Jean-Charles Soria, Patricia LoRusso, Ratislav Bahleda, et al.
Cancer Investigation
|
July 28, 2023
Platinum Sensitivity in <i>IDH1/2</i> Mutated Intrahepatic Cholangiocarcinoma: Not All "BRCAness" Is Created Equal
Deborah Blythe Doroshow, Wei Wei, Meenakshi Mehrotra, et al.
Journal of Cancer Therapy
|
September 24, 2013
Physicians' Use of Patients' Daily Reports of Quality of Life to Evaluate Treatment Response in Phase I Cancer Trials
Felicity W K Harper, Elisabeth I Heath, Marci E J Gleason, et al.
Page
of 17